Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combivent HFA Dose Confirmation in COPD
NCT02182674Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2000
- Primary completion
- Aug 2001
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ipratropium bromide, salbutamol in chronic obstructive pulmonary disease (COPD), sponsored by Boehringer Ingelheim. Started Oct 2000; status: completed.
02
Drugs
ipratropium bromidesalbutamol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02182674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182674.